Regeneron Pharmaceuticals 배당 및 자사주 매입

배당 기준 점검 0/6

Regeneron Pharmaceuticals 은(는) 현재 수익률이 0.59% 인 배당금 지급 회사입니다.

핵심 정보

0.6%

배당 수익률

6.0%

자사주 매입 수익률

총 주주 수익률	6.6%
미래 배당 수익률	0.6%
배당 성장률	n/a
다음 배당 지급일	n/a
배당락일	n/a
주당 배당금	n/a
배당 성향	4%

최근 배당 및 자사주 매입 업데이트

Recent updates

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Feb 04

Regeneron: Phase III Success In Skin Cancer For Libtayo

Jan 15

Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025

Jan 05

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Dec 13

Regeneron: Recent Bear Run May Be Justified -- Pharma Faces A Testing 2025

Dec 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings

Nov 22

Regeneron: The Biotech Stock To Buy Now

Nov 19

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: REGN US 시장에서 주목할만한 배당금을 지급하지 않으므로 지급이 안정적인지 확인할 필요가 없습니다.

배당금 증가: REGN US 시장에서 주목할만한 배당금을 지급하지 않으므로 지급액이 증가하는지 확인할 필요가 없습니다.

배당 수익률 vs 시장

Regeneron Pharmaceuticals 배당 수익률 vs 시장

REGN의 배당 수익률은 시장과 어떻게 비교되나요?
구분	배당 수익률
회사 (REGN)	0.6%
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.4%
업계 평균 (Biotechs)	2.6%
분석가 예측 (REGN) (최대 3년)	0.6%

주목할만한 배당금: REGN 의 배당금( 0.59% )은 US 시장에서 배당금 지급자의 하위 25%( 1.43% )와 비교해 주목할 만하지 않습니다.

고배당: REGN 의 배당금( 0.59% )은 US 시장에서 배당금 지급자의 상위 25%( 4.44% )와 비교해 낮습니다.

주주 대상 이익 배당

수익 보장: REGN US 시장에서 주목할만한 배당금을 지급하지 않습니다.

주주 현금 배당

현금 흐름 범위: REGN US 시장에서 주목할만한 배당금을 지급하지 않습니다.

높은 배당을 제공하는 우량 기업 찾기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/03 11:32
종가	2025/10/03 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Regeneron Pharmaceuticals, Inc.는 67명의 분석가가 다루고 있습니다. 이 중 24명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Regeneron Pharmaceuticals 배당 및 자사주 매입

배당 기준 점검 0/6

핵심 정보

최근 배당 및 자사주 매입 업데이트

Upcoming dividend of US$0.88 per share

Regeneron Pharmaceuticals, Inc. Declares A Cash Dividend on the Common Stock and Class A Stock, Payable on September 3, 2025

Upcoming dividend of US$0.88 per share

Regeneron Pharmaceuticals, Inc. Declares Cash Dividend on the Common Stock and Class A Stock, Payable on June 6, 2025

Regeneron Pharmaceuticals, Inc. Approves the Initiation of A Quarterly Cash Dividend Program and Declares A Cash Dividend, Payable on March 20, 2025

Recent updates

Regeneron Pharmaceuticals, Inc. to Report Q3, 2025 Results on Oct 28, 2025

Regeneron: Growth Catalysts Incoming

U.S. Food and Drug Administration Approves Evkeeza (Evkeeza-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi Announces That European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive CHMP Opinion

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva, Demonstrating That Garetosmab Prevents Greater Than 99% of Abnormal Bone Formation

Regeneron Pharmaceuticals, Inc. Announces Five-Year Follow-Up Results on Overall Survival from the Phase 3 Empower-Lung 3 Trial

Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron Pharmaceuticals, Inc. Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals Announces FDA Review Extension for EYLEA HD® Prefilled Syringe and Expanded Indications

Upcoming dividend of US$0.88 per share

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Declares A Cash Dividend on the Common Stock and Class A Stock, Payable on September 3, 2025

Regeneron Pharmaceuticals, Inc. Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myelomac

Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000 Growth Index

Regeneron Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 01, 2025

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Price target decreased by 7.4% to US$738

Regeneron Pharmaceuticals, Inc. Announces Interim Results from Ongoing Phase 2 Cloud Ridge Trial Confirm Potential to Improve the Quality of Semaglutide (Glp-1 Receptor Agonist)-Induced Weight Loss by Preserving Lean Mass

Investor sentiment deteriorates as stock falls 17%

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Regeneron Pharmaceuticals, Inc. Announces Initial Results from Two Cohorts of the Phase 1B Linker-Mm2 Trial Evaluating Linvoseltamab in Combination with Two Different Proteasome Inhibitors

Undisclosed acquirer proposed to acquire 23andMe Holding Co. (OTCPK:MEHC.Q) for approximately $260 million.

Upcoming dividend of US$0.88 per share

Price target decreased by 7.0% to US$797

Consensus EPS estimates fall by 15%

Regeneron Pharmaceuticals, Inc. Announces 24 Abstracts on Dupixent (Dupilumab) Clinical Data and Real-World Analyses in Respiratory Diseases

Price target decreased by 8.6% to US$808

Regeneron Pharmaceuticals, Inc. Declares Cash Dividend on the Common Stock and Class A Stock, Payable on June 6, 2025

First quarter 2025 earnings: EPS in line with expectations, revenues disappoint

Regeneron Pharmaceuticals, Inc. Announces Approval in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Provides Update on EYLEA HD®? (aflibercept) Injection 8 mg Supplemental Biologics License Application

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts EYLEA HD (aflibercept) Injection 8 mg

Biocon Biologics Ltd Announces Settlement and License Agreement with Regeneron

Regeneron: Still A Biotech Juggernaut

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2025

Dupixent And EYLEA Will Open New Therapeutic Frontiers

Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Ministry of Health, Labour and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab)

Regeneron Pharmaceuticals, Inc. to Report Q1, 2025 Results on Apr 29, 2025

Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad

Linvoseltamab Recommends for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts odronextamab BLA for the Treatment of Relapsed/Refractory Follicular Lymphoma

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

U.S. Food and Drug Administration Accepts Linvoseltamab BLA for the Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces First Presentation of Positive Results from the Phase 3 QUASAR Trial

Full year 2024 earnings: EPS misses analyst expectations

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Regeneron Pharmaceuticals, Inc. Approves the Initiation of A Quarterly Cash Dividend Program and Declares A Cash Dividend, Payable on March 20, 2025

Regeneron: Phase III Success In Skin Cancer For Libtayo

Regeneron Pharmaceuticals, Inc. Announces Adjuvant Libtayo (Cemiplimab) Significantly Improves Disease-Free Survival After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma in Phase 3 Trial

Gainey Mckenna & Egleston Files Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc

Regeneron Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 04, 2025

Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025

Regeneron Pharmaceuticals, Inc. to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-Concept Results

Regeneron Pharmaceuticals, Inc. Announces EYLEA HD Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Odronextamab Ash Presentations Underscore Impressive Potential in Early Lines of Treatment and Additional Types of Lymphoma

Regeneron Pharmaceuticals, Inc. Announces that Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieve Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Regeneron: Recent Bear Run May Be Justified -- Pharma Faces A Testing 2025

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings

Regeneron: The Biotech Stock To Buy Now

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024